Adra, N., Vulsteke, C., Loriot, Y., Rodriguez-Vida, A., Zhang, Z., Ku, J. H., Oláh, J., Kolodziej, A., Sabadash, M., Amsberg, G. V., Alimohamed, N. S., O'Donnell, P. H., Lychkovsky, O., Kulkarni, G. S., Lichfield, J., Meng, C., Huang, D., Ramamurthy, C., Moreno, B. H., Danchaivijitr, P. (2026). Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4613